How to Get Blue Hat Approval for a Nutraceutical in China: 2026 Guide
A comprehensive walkthrough of China’s health food registration pathway for nutraceutical companies — from ingredient assessment to post-approval compliance.
1. Introduction: What Is a Nutraceutical in China’s Regulatory System?
The term “nutraceutical” — a portmanteau of nutrition and pharmaceutical — is widely used in global markets to describe products that sit at the intersection of food and medicine. These include dietary supplements, functional foods, herbal extracts, probiotics, vitamins, minerals, and other bioactive compounds intended to deliver health benefits beyond basic nutrition.
In China, however, the term “nutraceutical” carries no formal legal definition. Instead, these products are regulated under a well-established category known as health foods (保健食品, bǎo jiàn shí pǐn). Once a product receives formal approval as a health food, it is granted the right to bear the iconic “Blue Hat” (蓝帽子, lán mào zi) logo — a blue, hat-shaped emblem that has become the single most recognized symbol of regulatory compliance and consumer trust in China’s supplement market.
The Blue Hat is not optional. Without it, a product cannot legally make any health-related claims in advertising, labeling, or marketing materials anywhere in mainland China. Gaining this approval is the single most important regulatory milestone for any nutraceutical company aiming to enter the Chinese market legitimately and at scale.
This 2026 guide provides a comprehensive, step-by-step walkthrough of the Blue Hat application process — covering ingredient assessment, safety and toxicology requirements, functional claim validation, manufacturing standards, the NMPA review pathway, timelines, costs, and ongoing compliance obligations. Whether you are an established multinational supplement company or a small functional-foods brand exploring China for the first time, the information that follows will give you a realistic, actionable roadmap.
2. Understanding China’s Classification: Health Foods (保健食品)
China’s food and drug regulatory framework, administered by the National Medical Products Administration (NMPA), divides products into three broad categories: ordinary foods (普通食品), health foods (保健食品), and drugs (药品). Nutraceuticals that make any structure-function or disease-risk-reduction claim fall under health foods.
Health foods themselves are subdivided into two regulatory tracks:
- Health Food Registration (注册): Overseen by the NMPA. Required for products using ingredients not already on the Directory of Health Food Ingredients, or for products making claims that require higher scrutiny. This is the more rigorous pathway and applies to most imported nutraceuticals.
- Health Food Filing (备案): Administered by provincial-level authorities. A simplified process available only for products whose ingredients are listed in the Directory and whose functional claims are standardised. Filing is faster and cheaper but is generally limited to domestic manufacturers and a narrow range of well-established ingredients (e.g., certain vitamins and minerals).
For most foreign nutraceutical companies, the registration pathway — the full Blue Hat approval — is the relevant route. Filing is often unavailable for imported products with novel ingredients or complex formulations.
Imported nutraceuticals must go through the full NMPA registration process. The simplified provincial filing pathway is largely restricted to domestic manufacturers using ingredients on the official Directory. As of 2026, this distinction remains firmly in place.
3. Pre-Application Strategy: Ingredient Assessment and Regulatory Planning
Before submitting a single document, you must determine whether each active ingredient in your formulation is already recognised within China’s regulatory framework. This is arguably the most consequential decision in the entire process.
3.1 The Directory of Health Food Ingredients
China publishes a Directory of Health Food Ingredients (保健食品原料目录), which lists substances that have been pre-approved for use in health foods. If your ingredient appears in this directory, you have a well-defined path forward. If it does not, you face a much longer and costlier process known as New Ingredient Registration.
3.2 New Ingredient Registration (新原料注册)
For ingredients not on the directory, the applicant must submit a full dossier including:
- Detailed chemical characterisation (structure, purity, stability)
- Manufacturing process and quality specifications
- Full toxicology battery (acute, sub-chronic, chronic, genotoxicity, reproductive/developmental)
- Metabolism and pharmacokinetic data
- Human safety and tolerance studies
- Proposed daily intake level with safety margin justification
New ingredient registration can add 12 to 24 months to the timeline and significantly increases costs. Many companies choose to reformulate using directory-listed ingredients rather than pursue this route.
3.3 Pre-Submission Consultation
Since 2021, the NMPA has offered formal pre-submission consultation meetings. We strongly recommend scheduling one. A 60- to 90-minute session with NMPA technical reviewers can identify fatal flaws in your application strategy before you invest in expensive testing.
4. Safety Assessment Requirements
China’s safety requirements for health foods are among the most rigorous in the world. The NMPA expects a comprehensive battery of tests conducted by NMPA-accredited laboratories — testing done at unaccredited facilities will not be accepted.
4.1 Toxicology Testing
The standard toxicology package for a health food registration includes:
- Acute oral toxicity: Single-dose study in two species (typically rat and mouse)
- 30-day or 90-day sub-chronic feeding study: In rodents, with full histopathology and clinical chemistry
- Genotoxicity battery: Ames test, chromosomal aberration test, and micronucleus test
- Teratogenicity / developmental toxicity: As required, depending on the ingredient and claim
- Metabolism and pharmacokinetics: Especially for novel or high-dose ingredients
4.2 Heavy Metals and Contaminant Limits
Chinese standards (GB 16740-2014 National Food Safety Standard for Health Foods) mandate strict limits:
| Contaminant | Maximum Limit |
|---|---|
| Lead (Pb) | ≤ 2.0 mg/kg (1.5 mg/kg for liquid products) |
| Arsenic (As, total) | ≤ 1.0 mg/kg |
| Mercury (Hg) | ≤ 0.3 mg/kg |
| Cadmium (Cd) | ≤ 0.3 mg/kg (1.0 mg/kg for herbal-based products) |
| Microbial limits | Total plate count ≤ 1,000 CFU/g; coliforms ≤ 0.4 MPN/g; no Salmonella, S. aureus, or other pathogens |
4.3 Microbiology and Stability
Beyond contaminant limits, you must submit:
- Three-batch microbiological testing (bacteria, yeast, mould, pathogens)
- Accelerated stability study (6 months at 40°C / 75% RH)
- Real-time stability study (24 months at controlled room temperature)
- Photostability and packaging compatibility data
5. Functional Claim Validation: The 27 Allowed Claims
China’s regulatory system does not allow open-ended health claims. The NMPA maintains a fixed list of 27 approved functional claims (功能声称), and your product’s claim must match one of these exactly. Partial or modified wording is not permitted.
Examples of the 27 approved claims include:
- Enhances immune function (增强免疫力)
- Assists in blood lipid reduction (辅助降血脂)
- Assists in blood glucose reduction (辅助降血糖)
- Improves sleep (改善睡眠)
- Relieves visual fatigue (缓解视疲劳)
- Promotes bone health (增加骨密度)
- Supports gastrointestinal health (改善胃肠道功能/润肠通便)
- Provides antioxidant effects (抗氧化)
- Enhances memory (辅助改善记忆)
- Reduces body fat (减肥)
- Alleviates physical fatigue (缓解体力疲劳)
5.1 Scientific Evidence Required
Each functional claim must be supported by a combination of:
- In vitro mechanistic studies demonstrating the biological rationale
- Animal studies using recognised disease models relevant to the claim
- Human clinical trials (see Section 8) conducted in Chinese populations
- Systematic literature reviews of existing clinical evidence, with an emphasis on Asian and Chinese studies
The NMPA places particular weight on studies conducted in Chinese subjects. Evidence based solely on Western populations is viewed as less persuasive. If your product is imported, you should anticipate needing at least one China-based clinical study.
No claim may imply disease diagnosis, treatment, or cure. For example, you can say “assists in blood pressure regulation” but absolutely cannot say “treats hypertension.” The NMPA treats such violations as drug misbranding, which carries severe penalties including market ban and fines.
6. Product Formula Review: Ratios, Excipients, and Herbal Rules
The NMPA will scrutinise every ingredient in your formulation, including excipients, carriers, and capsule shells. Key considerations include:
- Ingredient ratios: The relative proportions of all active ingredients must be justified by safety and efficacy data. An arbitrary blend without scientific rationale will be rejected.
- Excipient compliance: All inactive ingredients must appear on the NMPA’s list of permitted food additives (GB 2760). Non-standard excipients require separate approval.
- Chinese herbal ingredients: If your product contains any traditional Chinese medicine (TCM) herbs, additional restrictions apply. Some herbs are prohibited in health foods; others have maximum daily dose limits. The NMPA’s “List of Health Food Prohibited Ingredients” must be checked thoroughly.
- Crossover with drugs: The NMPA cross-references ingredient lists against its database of approved drugs. Any ingredient that is an active pharmaceutical ingredient (API) in China — even if sold as a supplement elsewhere — may be rejected or require reclassification as a drug.
- Novel forms: Liposomal formulations, nanoparticle delivery systems, and other novel technologies face additional scrutiny. You will need to demonstrate safety and bioavailability data specific to the delivery form.
7. Manufacturing Quality Standards: GMP and Facility Inspection
China requires all health food manufacturers — including foreign factories producing products for the Chinese market — to meet health food GMP (良好生产规范) standards. For imported products, the NMPA may conduct a remote or on-site facility inspection at the overseas production site.
7.1 GMP Requirements
Key GMP areas include:
- Facility design and environmental controls (air handling, zoning, sanitation)
- Raw material identity testing and supplier qualification
- In-process quality control and finished product testing
- Stability program and retained sample management
- Deviation, complaint, and recall procedures
- Personnel training and hygiene protocols
7.2 Foreign Facility Inspection
Since 2023, the NMPA has increased the frequency of overseas inspections. While random inspections are rare, a flagged application — for example, one involving a novel ingredient or an ambitious functional claim — increases the likelihood of an inspection. Companies should prepare by:
- Maintaining full batch records translated into Chinese
- Having a Chinese-speaking quality representative available
- Ensuring all certificates (ISO 22000, FSSC 22000, GMP) are current and translated
- Pre-emptively auditing against China’s specific GMP requirements (which differ from FDA/EU GMP in key areas such as raw material testing frequency and environmental monitoring standards)
8. Clinical Trial and Human Testing Requirements
Human clinical data is required for most Blue Hat applications, especially those making claims tied to disease risk reduction or physiological function enhancement. The NMPA publishes detailed technical standards (保健食品功能评价技术规范) that define acceptable study designs for each of the 27 functional claims.
8.1 Study Design Requirements
- Randomised, double-blind, placebo-controlled design is the gold standard and expected for most claims
- Sample size: Typically 100–200 subjects per arm, powered to detect the claimed effect
- Duration: Variable by claim (30 days for immune function; 60–90 days for blood lipid reduction; 6+ months for bone density claims)
- Chinese subjects: The study must be conducted on a mainland Chinese population at NMPA-recognised clinical trial sites
8.2 Ethical and Regulatory Approval
Before initiating a clinical trial in China, you must obtain:
- Ethics committee (IRB) approval from the trial site’s institutional review board
- Human trial registration with the Chinese Clinical Trial Registry (ChiCTR)
- Informed consent in Chinese from all participants
Clinical trials for health foods are generally classified as “low-risk” compared to drug trials, but they still face stringent oversight. Partnering with a Contract Research Organization (CRO) experienced in Chinese health food trials is strongly advised.
9. The Review Process: From Submission to Approval
Once your dossier is complete, the application enters the NMPA’s formal review pipeline. Here is the typical sequence of events:
- Submission to the NMPA Administrative Acceptance Office: All documents (in Chinese) are submitted through the NMPA’s online portal (e-approval system). The acceptance office conducts a 5–10 business day completeness check. Missing documents trigger a request for supplementary materials.
- Technical review by the NMPA Health Food Technical Review Committee: A panel of experts evaluates the safety, efficacy, and quality data. This stage typically takes 6–12 months and may involve formal questions (补充资料通知) requiring additional data or clarification. It is common to receive two or three rounds of questions.
- Expert panel evaluation (专家评审会): For complex or novel applications, the technical committee convenes an expert panel that meets in person or virtually to discuss the application. The panel votes on whether to recommend approval.
- NMPA final decision and certificate issuance: If the panel recommends approval, the NMPA issues the Health Food Registration Certificate (保健食品注册证书) and the product is granted Blue Hat status. The certificate includes the approved product name, ingredient list, daily dosage, and exact wording of the functional claim.
Summary Table: Blue Hat Approval Process at a Glance
| Step | Stage | Estimated Duration | Key Activities |
|---|---|---|---|
| 1 | Pre-application planning & ingredient assessment | 2–6 months | Ingredient review, regulatory strategy, pre-submission consultation |
| 2 | Safety & toxicology testing | 4–8 months | Acute/chronic tox, genotoxicity, heavy metals, microbiology |
| 3 | Functional claim scientific evidence | 3–6 months | Literature review, in vitro studies, animal model studies |
| 4 | Clinical trial (if required) | 6–12 months | IRB approval, subject recruitment, trial conduct, data analysis |
| 5 | Manufacturing GMP documentation | 2–4 months | Facility audit prep, batch records, quality manuals in Chinese |
| 6 | Dossier compilation & submission | 1–3 months | Translation, notarisation, online submission |
| 7 | NMPA technical review | 6–12 months | Reviewer questions, supplementary data submissions |
| 8 | Expert panel evaluation | 1–3 months | Panel meeting, recommendation vote |
| 9 | Final approval & certificate | 1–2 months | Certificate issuance, Blue Hat logo authorisation |
10. Approval Timeline and Cost Estimates (2026)
Realistic expectations are critical. The full Blue Hat registration process — from initial planning to certificate in hand — typically takes 18 to 24 months for a straightforward application using directory-listed ingredients and an existing evidence base. Novel ingredients or products requiring de novo clinical trials can stretch to 30–36 months.
10.1 Cost Breakdown
| Cost Item | Estimated Range (RMB) | Notes |
|---|---|---|
| Regulatory consulting & strategy | 150,000 – 400,000 | Chinese regulatory consultant, dossier preparation, translation |
| Toxicology & safety testing | 200,000 – 600,000 | Varies by number of ingredients and complexity of tox package |
| Functional claim studies (lab & animal) | 100,000 – 400,000 | Depending on claim type and number of required models |
| Clinical trial (human study) | 500,000 – 2,000,000+ | Single-centre vs. multi-centre, sample size, claim complexity |
| GMP documentation & facility readiness | 100,000 – 300,000 | Translation, gap analysis, mock audits |
| NMPA application & processing fees | 50,000 – 100,000 | Official government fees (varies by product type) |
| Supplementary data responses | 50,000 – 200,000 | Unplanned costs for additional testing or documentation |
| Total estimated range | 500,000 – 2,000,000+ RMB | ~$70,000 – $280,000+ USD |
Most companies underestimate the cost of supplementary data requests. It is wise to maintain a contingency reserve of at least 30% of your total budget for unexpected testing requirements or additional rounds of expert review questions.
11. Post-Approval Obligations: Labeling, Reporting, and Renewal
Receiving the Blue Hat is not the end of the journey; it marks the beginning of ongoing compliance obligations. Failure to meet these can result in suspension or revocation of the registration certificate.
11.1 Label Standards
Every Blue Hat product must display on its label:
- The Blue Hat logo (standard size and colour, no modification permitted)
- The text “Health Food (保健食品)”
- The exact registration number (e.g., 国食健注G2026XXXX)
- Approved product name, ingredient list, net content, and daily dosage
- The exact approved functional claim wording — no deviation allowed
- The mandatory disclaimer: “This product is not a substitute for medical treatment (本品不能代替药物)”
- Target population (if restricted), contraindications, and storage conditions
11.2 Annual Reporting
Registered health foods must submit an annual self-inspection report to the NMPA, covering:
- Production volumes and distribution records
- Adverse event monitoring (any consumer complaints or adverse reactions)
- Stability monitoring results for batches released during the year
- Any changes to the manufacturing process or facility
11.3 Renewal Every Five Years
The Health Food Registration Certificate is valid for five years. Renewal requires a fresh submission including updated safety data, ongoing stability data, and a summary of post-market surveillance. The renewal process is less onerous than the initial registration but still requires 6–12 months of lead time. Do not wait until the certificate expires — late renewal means a full re-registration.
11.4 Changes and Variations
Any change to the product formulation, manufacturing process, or label requires NMPA approval before implementation. Minor changes (e.g., packaging size) may be handled via notification; major changes (e.g., ingredient substitution) require a new registration. Always consult your regulatory agent before making any modifications.
12. Conclusion: Strategic Recommendations for Nutraceutical Companies
China’s Blue Hat approval process is one of the most rigorous nutraceutical regulatory pathways in the world. It demands significant time, capital, and regulatory expertise. However, for companies willing to invest properly, the reward is access to a market worth over ¥800 billion RMB (~$110 billion USD) and growing at 8–10% annually — a market where the Blue Hat logo commands instant consumer recognition and trust.
Based on our experience guiding dozens of nutraceutical companies through this process, we offer the following strategic recommendations:
Before committing to a specific formulation or claim, engage a qualified China regulatory consultant to audit your product against the Directory of Health Food Ingredients and the 27 approved claims. This single step can save you 12+ months and millions in wasted testing.
Even if your product is well-studied internationally, assume you will need at least one clinical trial in a Chinese population. Build this into your budget and timeline from day one.
Navigating NMPA-accredited labs, ethics committees, and the ChiCTR registration system requires on-the-ground expertise. A Chinese CRO with health food experience is worth every yuan.
The NMPA technical review almost always results in requests for additional data. Prepare a comprehensive dossier and maintain a war chest of contingency funds for unexpected testing.
Optimistic timelines are the enemy of realistic market entry planning. Evaluate your internal approval horizon, budget runway, and market launch expectations against a 24-month baseline — and celebrate if you beat it.
China Gateway 360 provides regulatory intelligence and market entry consulting for health, nutrition, and wellness brands entering the Chinese market. This guide is for informational purposes only and does not constitute legal or regulatory advice. Companies should engage qualified legal and regulatory professionals for their specific applications. Article ID: CG360-HEALTH-SUPPLEMENTS-GUID-005. Last updated: July 2026.
References & Further Reading:
NMPA — Health Food Registration Administrative Measures (保健食品注册与备案管理办法), 2023 Revision.
NMPA — Directory of Health Food Ingredients (保健食品原料目录), 2025 Edition.
GB 16740-2014 — National Food Safety Standard for Health Foods.
NMPA — Technical Standards for Health Food Functional Evaluation (保健食品功能评价技术规范), 2023.
